Market capitalization | $15.65m |
Enterprise Value | $7.54m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 17.53 |
P/S ratio (TTM) P/S ratio | 36.40 |
P/B ratio (TTM) P/B ratio | 0.63 |
Revenue growth (TTM) Revenue growth | -66.71% |
Revenue (TTM) Revenue | $430.00k |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Aptorum Group Limited Class A:
1 Analyst has issued a forecast Aptorum Group Limited Class A:
Dec '23 |
+/-
%
|
||
Revenue | 0.43 0.43 |
67%
67%
|
|
Gross Profit | -1.12 -1.12 |
1%
1%
|
|
EBITDA | -9.40 -9.40 |
42%
42%
|
EBIT (Operating Income) EBIT | -11 -11 |
40%
40%
|
Net Profit | -2.82 -2.82 |
71%
71%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aptorum Group Ltd. is a pharmaceutical company, which engages in the development and commercialization of therapeutic and diagnostic technologies. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, and other disease areas. The Non-Therapeutics segment encompasses the development of surgical robotics and medical devices; and the activities of AML Clinic. The company was founded by Ian Huen on September 13, 2010 and is headquartered in Hong Kong.
Head office | Cayman Islands |
CEO | Ian Huen |
Employees | 3 |
Founded | 2010 |
Website | www.aptorumgroup.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.